Study Of Candonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
Candonilimab（AK104）is a humanized IgG1 bispecific antibody that targets PD-1 and CTLA-4.
This is a single-arm, multicenter, open-label, phase II study, the purpose of this study is
to evaluate the efficacy and safety of candonilimab plus radiotherapy in participants with
locally advanced cervical cancer who do not tolerate chemotherapy.